Atilla, E. Et Al. 2015. Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?. 57th Annual Meeting of the American-Society-of-Hematology , (Florida, United States Of America).

Atilla, E., Ataca, P., TOPRAK, S. K., YÜKSEL, M., TOPÇUOĞLU, P., ARSLAN, Ö., ... ÖZCAN, M.(2015). Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant? . 57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America

Atilla, Erden Et Al. "Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?," 57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 2015

Atilla, Erden Et Al. "Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?." 57th Annual Meeting of the American-Society-of-Hematology , Florida, United States Of America, 2015

Atilla, E. Et Al. (2015) . "Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?." 57th Annual Meeting of the American-Society-of-Hematology , Florida, United States Of America.

@conferencepaper{conferencepaper, author={Erden Atilla Et Al. }, title={Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?}, congress name={57th Annual Meeting of the American-Society-of-Hematology}, city={Florida}, country={United States Of America}, year={2015}}